Novo Nordisk A/S (NVO)
|Net Income (ttm)
|Mar 22, 2024
|119.79 - 122.13
|67.66 - 124.87
|Jan 31, 2024
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.Financial numbers in DKK Financial Statements
According to 5 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $100.1, which is a decrease of -17.95% from the latest price.
Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.
The Ozempic and GLP-1 weight loss trend parallels the artificial intelligence (AI) mania that's gone mainstream viral, sending stocks like Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA thro...
Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...
Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.
Growing demand for megacap stocks that tap global secular growth trends has catapulted European shares to fresh highs, although some say their star may wane as investors seek value elsewhere.
Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic...
Bagsværd, Denmark, 19 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement w...
U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks.
The feverish craze for Wegovy, Ozempic and other GLP-1 drugs is not over. It is prompting food executives to call the top boss at Novo Nordisk to ask for advice.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 14 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated per...
Goldman Sachs Says 'GRANOLAS' Stocks Are Set to Enjoy Further Gains
Large-cap European firms with a global footprint and strong balance sheets have outperformed the 'Magnificent Seven' US stocks and are poised for further gains, according to Sharon Bell, senior Europe...
For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.
Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.
Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's paren...
Novo Nordisk CEO on Catalent, Ozempic and Wegovy
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. F...
U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line, ac...
Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.
Bio-pharma services are key to our strategy: Novo Holdings CEO
Kasim Kutay, CEO of Novo Holdings, discusses Novo Holdings acquisition of U.S.-based medicines manufacturer Catalent.
Novo Holdings, the holding company of Novo Nordisk , said on Tuesday it was investing in Indian private hospital chain Manipal Hospitals, its largest investment in Asia to date.
Big drug companies have substantial free cash flow from older, cash-cow drugs, manageable debt burdens, and investor pressure to find new growth opportunities.
Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.
Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.